Skip to main content

Advertisement

Table 5 AEs occurring in ≥ 2% of patients

From: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

  BF Spiromax (N = 197) BF Turbuhaler (N = 197)
Patients with at least 1 AE, n (%) 113 (57.4) 119 (60.4)
 Infections and infestations
  Lower respiratory tract infection 17 (8.6) 31 (15.7)
  Urinary tract infection 5 (2.5) 2 (1.0)
 Nervous system disorders
  Headache 5 (2.5) 2 (1.0)
 Respiratory, thoracic, and mediastinal disorders
  Asthma (worsening of asthma or asthma attack) 8 (4.1) 9 (4.6)
  Cough 11 (5.6) 12 (6.1)
  Dyspnea 5 (2.5) 5 (2.5)
  Wheezing 4 (2.0) 3 (1.5)
Number of patients with at least 1 serious AE, n (%) 4 (2.0) 8 (4.1)
  1. AE adverse event, BF budesonide formoterol